Tel Aviv Managing Shareholder Joey Shabot and Of-Counsel Ephraim Schmeidler recently represented a US-based family office as part of its investment into Israeli company Sight Diagnostics Ltd (Sight). Sight develops a platform for diagnosing blood diseases using computer vision technology and is a portfolio company of Clal Biotechnology Industries Ltd., traded on the Tel Aviv Stock Exchange. This investment was part of a $28 million investment round.
Read more here